Abstract

This was a prospective observational study which was performed for assessing the safety and efficacy of netarsudil ophthalmic solution in patients with pre-perimetric glaucoma as a first-line therapy.
40 eyes of 20 patients with pre-perimetric glaucoma/ early POAG, having an RNFL defect were prescribed netarsudil monotherapy. The mean IOP at baseline of the affected eyes was 19.27±3.180mmHg (mean ± standard deviation) which reduced to 16.50±2.28, p=0.01 (14% reduction). The adverse effects experienced by patients were not severe in the majority of cases. Some adverse effects observed were redness, irritation or itching seen in 10 eyes (25%). The average RNFL thickness at baseline was 83.18±10.59 and at 8mths was 81.32±9.54, p=0.089. The average GCC thickness at baseline was 74.09±9.78 and at 8mths was 72.91±11.73, p=0.18. On OCTA, the baseline and 8mths follow-up were comparable.